Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. REBYOTA™ Prospective Registry

   Completed · Recurrence of Clostridium Difficile Infection

   NCT05835219 · Ferring Pharmaceuticals As · 38 U.S. investigators

   $234,684research payments

2. A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

   Recruiting · Phase 2 · Colorectal Cancer

   NCT07023289 · AbbVie Inc. · 10 U.S. investigators

   $234,673research payments

3. A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

   Terminated · Phase 3 · Crohn Disease

   NCT03464097 · Celgene Corporation · 26 U.S. investigators

   $234,490research payments

4. A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome

   Completed · Phase 1, Phase 2 · Angelman Syndrome

   NCT04259281 · Ultragenyx Pharmaceutical Inc. · 6 U.S. investigators

   $234,341research payments

5. Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)

   Completed · Homocystinuria Due to CBS Deficiency

   NCT02998710 · Travere Therapeutics, Inc. · 6 U.S. investigators

   $233,554research payments

6. Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

   Completed · Phase 3 · Hereditary Angioedema

   NCT04739059 · Csl Behring · 9 U.S. investigators

   $233,422research payments

7. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

   Recruiting · Phase 3 · Metabolic Dysfunction-Associated Steatotic Liver Disease

   NCT07165028 · Eli Lilly and Company · 92 U.S. investigators

   $233,324research payments

8. A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

   Completed · Phase 1 · Leiomyosarcoma

   NCT03761095 · Ptc Therapeutics, Inc. · 3 U.S. investigators

   $233,153research payments

9. FX Shoulder Solutions Retrospective / Prospective Clinical Study

   Recruiting · Rotator Cuff Syndrome of Shoulder and Allied Disorders

   NCT06077942 · Fx Shoulder Solutions, Inc · 0 U.S. investigators

   $232,517research payments

10. Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose

    Completed · Phase 3 · Dengue Fever

    NCT03999996 · Takeda Pharmaceuticals U.S.A., Inc. · 8 U.S. investigators

    $231,638research payments

11. A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants

    Completed · Phase 1 · Healthy

    NCT06311656 · Eli Lilly and Company · 1 U.S. investigator

    $231,484research payments

12. A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)

    Recruiting · Phase 2 · Complicated Intra-abdominal Infections (cIAI)

    NCT06794541 · Tetraphase Pharmaceuticals, Inc. · 5 U.S. investigators

    $231,378research payments

13. Evaluation of the Effects of a Biostimulator and Dermal Fillers for Cheek Augmentation and Contour Deficiencies

    Completed · Not applicable · Photoaging

    NCT06351358 · Galderma Laboratories, L.P. · 2 U.S. investigators

    $231,035research payments

14. A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort

    Recruiting · Phase 1 · Duchenne Muscular Dystrophy

    NCT04626674 · Sarepta Therapeutics, Inc. · 5 U.S. investigators

    $230,150research payments

15. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

    Recruiting · Phase 3 · Ulcerative Colitis

    NCT06937086 · Eli Lilly and Company · 9 U.S. investigators

    $230,051research payments

16. A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    Active, not recruiting · Phase 1 · Chronic Lymphocytic Leukemia

    NCT06291220 · AbbVie Inc. · 7 U.S. investigators

    $228,299research payments

17. Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:

    Completed · Phase 2 · Locally Advanced Pancreatic Carcinoma(LAPC)

    NCT03861702 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $226,808research payments

18. A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

    Enrolling by invitation · Phase 2 · Melanoma

    NCT06848088 · Regeneron Pharmaceuticals, Inc. · 6 U.S. investigators

    $226,775research payments

19. Observational Evaluation of Atopic Dermatitis in Pediatric Patients

    Active, not recruiting · Dermatitis Atopic

    NCT03687359 · Sanofi US Services Inc. · 19 U.S. investigators

    $226,115research payments

20. Epco, Zanu, Ritux for R/R FL or MZL

    Recruiting · Phase 2 · Follicular Lymphoma

    NCT06563596 · Beone Medicines USA, Inc. · 1 U.S. investigator

    $226,046research payments

21. BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

    Recruiting · Phase 1 · Hormone-receptor-positive Breast Cancer

    NCT06756932 · Beone Medicines Ltd. · 5 U.S. investigators

    $226,010research payments

22. A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia

    Active, not recruiting · Phase 3 · Friedreich Ataxia

    NCT05515536 · Ptc Therapeutics, Inc. · 5 U.S. investigators

    $224,508research payments

23. Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

    Completed · Phase 1, Phase 2 · Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)

    NCT02315326 · AbbVie Inc. · 1 U.S. investigator

    $222,544research payments

24. Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne

    Recruiting · Phase 1, Phase 2 · Acne

    NCT07013747 · Sanofi Pasteur Inc. · 3 U.S. investigators

    $221,742research payments

25. Optima Coil Performance in The Interventional Management of Intracranial Aneurysms Registry

    Recruiting · Intracranial Aneurysm

    NCT06282939 · Balt USA, LLC · 2 U.S. investigators

    $221,238research payments

26. EDX110 Randomized Control Trial for Treatment of DFUs

    Active, not recruiting · Not applicable · Wound Heal

    NCT07209358 · Convatec Inc. · 3 U.S. investigators

    $221,104research payments

27. A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis

    Terminated · Phase 1 · ALS

    NCT04948645 · AbbVie Inc. · 7 U.S. investigators

    $220,932research payments

28. HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

    Completed · Phase 3 · Hemophilia B

    NCT03569891 · Csl Behring · 14 U.S. investigators

    $220,438research payments

29. AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

    Recruiting · Not applicable · Coronary Arterial Disease (CAD)

    NCT06959524 · Boston Scientific Corporation · 10 U.S. investigators

    $219,872research payments

30. EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

    Completed · Phase 4 · Chronic Rhinosinusitis With Nasal Polyps

    NCT04998604 · Genzyme Corporation · 10 U.S. investigators

    $219,506research payments

31. Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)

    Completed · Not applicable · Dry Eye

    NCT04795752 · Sight Sciences, Inc. · 16 U.S. investigators

    $219,026research payments

32. Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

    Completed · Phase 3 · Parkinson's Disease (PD)

    NCT04379050 · AbbVie Inc. · 10 U.S. investigators

    $218,334research payments

33. Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

    Terminated · Not applicable · Stroke

    NCT02928497 · Boston Scientific Corporation · 50 U.S. investigators

    $217,768research payments

34. A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

    Active, not recruiting · Phase 3 · Multiple Myeloma

    NCT05827016 · Celgene Corporation · 23 U.S. investigators

    $217,449research payments

35. Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps

    Recruiting · Phase 3 · Chronic Rhinosinusitis Without Nasal Polyps

    NCT06850805 · Paratek Pharmaceuticals, Inc. · 11 U.S. investigators

    $216,446research payments

36. Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer

    Status unknown · Phase 1 · Pancreatic Adenocarcinoma

    NCT03703063 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $216,365research payments

37. Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

    Recruiting · Phase 1, Phase 2 · Recurrent Solid Tumor

    NCT04901702 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $215,208research payments

38. Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation

    Active, not recruiting · Not applicable · Paroxysmal Atrial Fibrillation

    NCT05462145 · Kardium Inc. · 9 U.S. investigators

    $215,118research payments

39. Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder

    Completed · Phase 3 · Schizophrenia

    NCT03187769 · Alkermes, Inc. · 0 U.S. investigators

    $215,040research payments

40. Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study

    Recruiting · Not applicable · Chronic Subdural Hematoma

    NCT06347796 · Balt USA, LLC · 2 U.S. investigators

    $215,000research payments

41. Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

    Recruiting · Phase 2 · High-risk Smoldering Multiple Myeloma

    NCT05469893 · Menarini Silicon Biosystems, Inc. · 1 U.S. investigator

    $214,938research payments

42. A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

    Recruiting · Phase 3 · Prurigo Nodularis

    NCT06293053 · Sanofi US Services Inc. · 10 U.S. investigators

    $214,763research payments

43. Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

    Recruiting · Phase 2 · Chronic Lymphocytic Leukemia (CLL)

    NCT04895436 · AbbVie Inc. · 9 U.S. investigators

    $214,177research payments

44. DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

    Completed · Phase 3 · Breast Cancer

    NCT03523585 · Daiichi Sankyo Inc. · 20 U.S. investigators

    $213,932research payments

45. Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)

    Recruiting · Phase 2 · Kidney Transplant

    NCT06919003 · Csl Behring · 2 U.S. investigators

    $213,581research payments

46. The PERSEVERE Study

    Recruiting · Not applicable · Pulmonary Embolism

    NCT06588634 · Stryker Corporation · 11 U.S. investigators

    $213,070research payments

47. Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis

    Completed · Phase 3 · Renal Failure

    NCT03183245 · Humacyte Global, Inc. · 22 U.S. investigators

    $211,814research payments

48. Study of Tazemetostat in Lymphoid Malignancies

    Terminated · Phase 1 · T-cell Lymphoma

    NCT05983965 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $211,014research payments

49. A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome

    Completed · Phase 3 · Dravet Syndrome

    NCT06118255 · UCB Biosciences Inc. · 5 U.S. investigators

    $210,641research payments

50. A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

    Recruiting · Phase 2 · Schizophrenia

    NCT07145918 · AbbVie Inc. · 5 U.S. investigators

    $210,155research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.